The role of RNA modification in the generation of acquired drug resistance in glioma DOI Creative Commons
Yu Yan, Wei Wei, Shengrong Long

et al.

Frontiers in Genetics, Journal Year: 2022, Volume and Issue: 13

Published: Nov. 11, 2022

Glioma is the most common malignant tumor in central nervous system. The clinical treatment strategy mainly surgery combined with concurrent temozolomide chemotherapy, but patients can develop drug resistance during treatment, which severely limits its therapeutic efficacy. Epigenetic regulation at RNA level plastic and adaptable, it induce a variety of responses to drugs. regulators modification include methyltransferases, demethylases, methylation binding proteins; these are also considered play an important role development, prognosis, response gliomas, provides basis for finding new targets epigenetic drugs resetting sensitivity cells temozolomide. This review discusses relationship between development adaptive glioma summarizes progress several major strategies this field, especially m6A modification, m5C adenosine-to-inosine editing.

Language: Английский

RNA modifications in long non-coding RNAs and their implications in cancer biology DOI
Jiexin Li, Xiansong Wang, Hongsheng Wang

et al.

Bioorganic & Medicinal Chemistry, Journal Year: 2024, Volume and Issue: 113, P. 117922 - 117922

Published: Sept. 13, 2024

Language: Английский

Citations

3
Long Non-Coding RNAs in Malignant Human Brain Tumors: Driving Forces Behind Progression and Therapy DOI Open Access

Dakun Pei,

Dandan Zhang, Yan Guo

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(2), P. 694 - 694

Published: Jan. 15, 2025

Long non-coding RNAs (lncRNAs) play a pivotal role in regulating gene expression and are critically involved the progression of malignant brain tumors, including glioblastoma, medulloblastoma, meningioma. These lncRNAs interact with microRNAs (miRNAs), proteins, DNA, influencing key processes such as cell proliferation, migration, invasion. This review highlights multifaceted impact lncRNA dysregulation on tumor underscores their potential therapeutic targets to enhance efficacy chemotherapy, radiotherapy, immunotherapy. The insights provided offer new directions for advancing basic research clinical applications tumors.

Language: Английский

Citations

0
Wilms’ Tumor: A Review of Clinical Characteristics, Treatment Advances, and Research Opportunities DOI Creative Commons

Mihai Cristian Neagu,

Vlad Laurenţiu David, Emil Radu Iacob

et al.

Medicina, Journal Year: 2025, Volume and Issue: 61(3), P. 491 - 491

Published: March 12, 2025

Nephroblastoma is a complex childhood cancer with generally favorable prognosis, well-defined incidence, and demographic profile but significant challenges in terms of recurrence long-term health outcomes. Although the management this pathology has evolved, leading to improved survival rates, continued research into effects treatment genetic factors influencing its development still required. The landscape for Wilms tumor evolving, emerging focusing on therapeutic biomarkers predispositions that influence efficacy rates. Identifying predictors response, such as specific markers histologic features, emerges critical area study could refine future interventions. complex, taking account stage disease, histological classification, individual patient factors, including age presence syndromic associations. As paradigms evolve, integration precision medicine approaches may enhance ability clinicians personalize improve outcomes broader range patients. Recent advances technology, machine-learning approaches, have facilitated identification correlate clinical This innovative method enhances integrate data predict disease trajectory response.

Language: Английский

Citations

0
RETRACTED ARTICLE: Breast cancer prognosis and immunological characteristics are predicted using the m6A/m5C/m1A/m7G-related long noncoding RNA signature DOI
Lína Zhang, Chengyu Liu, Xiaochong Zhang

et al.

Functional & Integrative Genomics, Journal Year: 2023, Volume and Issue: 23(2)

Published: April 4, 2023

Language: Английский

Citations

9
Identification of RNA methylation-related lncRNAs for prognostic assessment and immunotherapy in bladder cancer—based on single cell/Bulk RNA sequencing data DOI

LianMing Fan,

Jie Wang,

Zhiya Zhang

et al.

Functional & Integrative Genomics, Journal Year: 2024, Volume and Issue: 24(2)

Published: March 13, 2024

Language: Английский

Citations

2
Quantitative profiling N1-methyladenosine (m1A) RNA methylation from Oxford nanopore direct RNA sequencing data DOI

Shenglun Chen,

Jia Meng, Yuxin Zhang

et al.

Methods, Journal Year: 2024, Volume and Issue: 228, P. 30 - 37

Published: May 18, 2024

Language: Английский

Citations

2
The role of m5C RNA modification in cancer development and therapy DOI Creative Commons

Li Yu,

Hongen Xu, Hanchu Xiong

et al.

Heliyon, Journal Year: 2024, Volume and Issue: 10(19), P. e38660 - e38660

Published: Sept. 27, 2024

Language: Английский

Citations

2
RNA Modifications Meet Tumors DOI Creative Commons
Zhiyuan Yang, Siyu Zhang, Tian Xia

et al.

Cancer Management and Research, Journal Year: 2022, Volume and Issue: Volume 14, P. 3223 - 3243

Published: Nov. 1, 2022

Abstract: RNA modifications occur through the whole process of gene expression regulation, including transcription, translation, and post-translational processes. They are closely associated with expression, stability, cell cycle. in tumor cells play a vital role development metastasis, changes microenvironment, drug resistance tumors, construction cell-cell “internet”, etc. Several types have been identified to date various effects on biological characteristics different tumors. In this review, we discussed function modifications, N 6 -methyladenine (m A), 5-methylcytosine 5 C), 7 -methyladenosine G), 1 pseudouridine (Ψ), adenosine-to-inosine (A-to-I), microenvironment therapy solid liquid Keywords: tumor, modification, non-coding RNA,

Language: Английский

Citations

11
Comprehensive analysis of cuproptosis-related lncRNAs model in tumor immune microenvironment and prognostic value of cervical cancer DOI Creative Commons
Qiang Wang, Yue Xu

Frontiers in Pharmacology, Journal Year: 2022, Volume and Issue: 13

Published: Nov. 30, 2022

Cervical cancer (CC) is the fourth leading gynecological malignancy in females worldwide. Cuproptosis, a form of cell death induced by copper, elicits novel therapeutic strategy anticancer therapy. Nonetheless, effects cuproptosis-related lncRNAs CC remain unclear. Therefore, we aim to investigate lncRNAs, develop risk model for prognostic prediction, and elucidate immunological profile CC. Transcription profiles clinical follow-up data were retrieved from The Cancer Genome Atlas (TCGA) database. Afterward, was built distinguishing using least absolute shrinkage selection operator (LASSO) Cox regression. correctness validated, nomogram established followed tumor immune microenvironment analysis. Tumor dysfunction exclusion (TIDE) scores used assess immunotherapy response, pharmaceutical half-maximal inhibitory concentration (IC50) prediction performed potential chemotherapy medicines. Finally, through coexpression analysis, 199 collected. A unique generated 6 selected lncRNAs. score reliable independent survival with higher diagnostic effectiveness compared generic characteristics. Immunological infiltration investigation indicated that substantially linked patients’ immunology, low-risk patients had lower TIDE increased checkpoint expression, suggesting stronger response. Besides, high-risk group exhibited distinct sensitivity medications. immune-related progression connected differentially expressed genes (DEGs) between groups. Generally, comprised may help predict overall survival, indicate immunocyte infiltration, identify individualized treatment.

Language: Английский

Citations

10
Using integrated analysis from multicentre studies to identify RNA methylation-related lncRNA risk stratification systems for glioma DOI Creative Commons

Fanxuan Huang,

Xinyu Wang,

Junzhe Zhong

et al.

Cancer Cell International, Journal Year: 2023, Volume and Issue: 23(1)

Published: Aug. 5, 2023

N6-methyladenosine (m6A), 5-methylcytosine (m5C) and N1-methyladenosine (m1A) are the main RNA methylation modifications involved in progression of cancer. However, it is still unclear whether methylation-related long noncoding RNAs (lncRNAs) affect prognosis glioma.We summarized 32 m6A/m5C/m1A-related genes downloaded RNA-seq data clinical information from The Cancer Genome Atlas (TCGA) database. Differential expression analysis weighted gene co-expression network (WGCNA) were used to identify differentially expressed (DE-) lncRNAs order construct a prognostic signature glioma determine their correlation with immune function, therapy drug sensitivity. In vitro vivo assays performed elucidate effects on glioma.A total ten survival signature, which had good independent prediction ability for patients. It was found that high-risk group worse overall (OS) than low-risk all cohorts. addition, risk informed immunotherapy response sensitivity patients different subgroups. Knockdown RP11-98I9.4 RP11-752G15.8 induced more invasive phenotype, accelerated cell growth apparent resistance temozolomide (TMZ) both vivo. We observed significantly elevated global m5C m6A levels cells.Our study determined implication gliomas, established an lncRNA model, elucidated could suppress proliferation, migration TMZ resistance. future, these may become new choice glioma.

Language: Английский

Citations

6